Cannabis-derived medicinal products recommended to be available on prescription

“The ACMD has recommended that cannabis-derived medicinal products should be placed in Schedule 2 of the Misuse of Drugs Regulations 2001.”

It has been announced by the Advisory Council on the Misuse of Drugs (ACMD) that clinicians in the UK should have the option to prescribe cannabis-derived medicinal to patients.

The council has requested the Department of Health and Social Care and the Medicines and Healthcare Products Regulatory Agency to produce a definition for these products to move them out of schedule 1 and into schedule 2.

Read the full announcement here

Share on facebook
Share on google
Share on twitter
Share on linkedin

Published on